Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=235 TearCare System to Treat Dry Eye Disease
Dry Eye · Meibomian Gland Dysfunction
Primary: Change in Tear Break-Up Time (TBUT) From Baseline — 3.02; 2.58 Seconds
Phase 4 N=31 Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
N/A N=26 Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
Dry Eye
Primary: Difference Between Keratometric Tear Break Up Time (KTBUT) and Fluorescein Tear Break Up Time (FTBUT) — 5.95; 5.39 time in seconds — p=0.074
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
N/A N=55 TrueTear in Sjogren's Disease Patients
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
N/A N=29 Study of the TearCare System in Dry Eye Disease
Dry Eye
Primary: Mean Change in Tear Break-Up Time (TBUT) at 1-month From Baseline — 3.1 seconds
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=35 Evaluation of Ocular Comfort With ISTA Tears vs Systane
Dry Eye Disease
Primary: Percentage of Participants With Preference for One of the Treatments — 23; 1; 11 Participants
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
Phase 2 N=9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
N/A N=14 Meibomian Gland Dysfunction Treatment
Meibomian Gland Dysfunction · Dry Eye
Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Phase 3 N=93 Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
N/A N=314 TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Diagnostic Test Data for Disease Using Tear Osmolarity Threshold > 308 mOsm/L — 177; 14; 47; 61 participants
N/A N=91 Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency
Dry Eye Syndrome · Lipid Deficiency
Primary: Mean Bulbar Conjunctival Staining — 0.743; 0.442; 0.531; 0.443 percentage of staining
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
N/A N=55 Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
N/A N=29 DAILIES TOTAL1® - Comparative Assessment of Tear Film Evaporation
Refractive Error
Primary: Tear Film Evaporation Rate — 120.88; 105.63 gm^-2 h
N/A N=12 Pilot Study of TearCare System - Long-Term Extension
Dry Eye Syndromes
Primary: Mean Change in Tear Break-Up Time From Extension Study Baseline to Month 1 — 12.4 seconds
N/A N=16 Tear Film Break-up Time After Instillation of Artificial Tears
Keratoconjunctivitis Sicca
Primary: Noninvasive Tear Film Break-up Time — 14.67; 7.4 seconds
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
Phase 2 N=69 Safety and Efficacy of TOP1630 for Dry Eye Syndrome
Dry Eye Syndrome
Primary: Visual Acuity — 0.05; -0.09; 0.017; 0.075 logMAR
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…